Contineum Therapeutics, Inc. Class A Common Stock
CTNM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $283,519 | $389,295 | $387,014 | $387,014 |
| - Cash | $21,943 | $15,526 | $5,569 | $4,630 |
| + Debt | $6,259 | $193,192 | $138,331 | $4,909 |
| Enterprise Value | $267,835 | $566,961 | $519,776 | $387,293 |
| Revenue | $0 | $50,000 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | -$258 | $50,000 | -$329 | $0 |
| % Margin | – | 100% | – | – |
| EBITDA | -$42,000 | $23,573 | -$23,536 | -$28,336 |
| % Margin | – | 47.1% | – | – |
| Net Income | -$42,258 | $22,720 | -$24,253 | -$29,001 |
| % Margin | – | 45.4% | – | – |
| EPS Diluted | -2.18 | 0.9 | -0.97 | -1.15 |
| % Growth | -342.2% | 192.8% | 15.7% | – |
| Operating Cash Flow | -$32,845 | $19,349 | -$20,121 | -$26,266 |
| Capital Expenditures | -$514 | -$414 | -$118 | -$168 |
| Free Cash Flow | -$33,359 | $18,935 | -$20,239 | -$26,434 |